Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis  Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,

Published by Modified over 5 years ago

Similar presentations

Presentation on theme: "Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis  Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,"— Presentation transcript:

1 Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis 
Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert, PhD, Kristel Van Steen, PhD, Thibaut Van Zele, MD, PhD, Frederic Acke, MD, Natalie De Ruyck, MSc, Katrien Blomme, MSc, Ana R. Sousa, PhD, Richard P. Marshall, MD, PhD, Claus Bachert, MD, PhD  Journal of Allergy and Clinical Immunology  Volume 128, Issue 5, Pages e8 (November 2011) DOI: /j.jaci Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 A, Mean CFB in TPS based on LOCF for the treated (solid line) and placebo (dashed line) groups starting at the moment of first administration. Error bars indicate 95% CIs of the mean based on normal approximation. B, Baseline and week 8 TPSs in absolute values based on LOCF for each subject and divided into the mepolizumab-treated and placebo groups. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Mean CFB in serum ECP levels, blood eosinophil counts, serum IL-5Rα levels, and nasal MPO levels and mean nasal IL-1β and IL-5Rα levels (all in micrograms per liter), imputing 0 for observations of less than the LDL. These representations are based on LOCF and show the mepolizumab-treated (solid line) and placebo (dashed line) groups starting at the moment of first administration. Error bars indicate 95% CIs of the mean based on normal approximation. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Proportion of patients still in the study in the mepolizumab-treated (solid line) and placebo (dashed line) groups starting at the moment of first administration. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig E1 Study outline showing the different patient visits and the respective investigations. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig E2 Proportional improvement in CT scan scores based on LOCF for the mepolizumab-treated (black columns) and placebo (gray columns) groups rated by 3 different observers (A, B, and C). Error bars indicate 95% CIs of the proportion based on normal approximation. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig E3 Mean CFB in nPIF based on LOCF for the treated (solid line) and placebo (dashed line) groups starting at the moment of first administration. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8 Fig E4 Individual values of serum ECP levels, blood eosinophil counts, serum IL-5Rα levels, and nasal MPO levels (all in micrograms per liter) at weeks 0 and 8 based on LOCF for the mepolizumab-treated and placebo groups. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

9 Fig E5 Mean CFB in TPS based on LOCF for responders (solid line) and nonresponders (dashed line) starting at the moment of first administration. Error bars indicate 95% CIs of the mean based on normal approximation. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis  Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,"

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Nasal challenge with allergen leads to maxillary sinus inflammation
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,
Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.
Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity  Andrei Malinovschi,

Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity  Andrei Malinovschi,
Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,
Risk of an asthma exacerbation after bariatric surgery in adults

Risk of an asthma exacerbation after bariatric surgery in adults
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 
Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD 

Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Oral steroids and doxycycline: Two different approaches to treat nasal polyps  Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,

Oral steroids and doxycycline: Two different approaches to treat nasal polyps  Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Similar presentations

Ads by Google